Our team is focused on identifying the most suitable cancer treatment strategies and treatment biomarkers to enable precision oncology. We use bioinformatic and machine learning approaches to analyse cancer molecular profiling data, including genomic, transcriptomic and DNA methylation data, to link it with treatment responses and patient outcomes. Our research spans multiple solid cancer types, including ovarian, endometrial and lung cancers.
Current Research
- Studying mechanisms of PARP inhibitor response and resistance in homologous recombination deficient cancers, including ovarian and breast cancers
- Understanding the molecular mechanisms underpinning treatment response and acquired resistance in lung adenocarcinoma with KRAS mutations
- Identifying genomic predictors of progestin response in endometrial cancer
- Using machine learning and tumour microenvironment profiling in breast cancer prognosis
- Using machine learning and cancer genome sequencing to model pathogenicity of BRCA1/2 genetic variants
Staff
- Dr Olga Kondrashova, Team Head
- Brett Liddell, Bioinformatician
- Dr Jacinta Simmons, Research Officer
- Dr Lauren Ashwood, Research Officer
- Lijun Xu, Production Assistant
Internal Collaborators
- Professor Amanda Spurdle, Molecular Cancer Epidemiology
- Dr Nic Waddell, Medical Genomics
- John Pearson, Genome Informatics
External Collaborators
- Professor Clare Scott, WEHI
- Associate Professor Kate Sutherland, WEHI
- Professor Andreas Strasser, WEHI
- Professor Marco Herold, WEHI
- Associate Professor Marian Burr, ANU
- Dr Po-Ling Inglis, RBWH
- Dr Amy McCart Reed, UQCCR
- Professor Andreas Obermair, UQCCR
- Dr Garrett Frampton, Foundation Medicine
We gratefully acknowledge the support of the following organisations and funding bodies:
- National Health and Medical Research Council (NHMRC)
- Metro North Heath and Hospital Service (MNHHS)
- QIMR Berghofer